In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes ...

Layoffs are looming in Switzerland as Novartis announces its plans to cut upwards of 550 full-time positions by the end of ...

Businesses want to be available to provide for employees and be competitive. They want workers to be able to go to the HR ...

AI and computational modeling are reducing reliance on animal testing by simulating human biology, improving drug safety and ...

Aidoc's multi-triage device, powered by the CARE Foundation Model, detects and prioritizes multiple abdominal conditions with high accuracy, submitted for FDA approval. Aidoc's AI device enhances ...

A chemical engineer with a major in finance, the India-native Kanumuri came to the US in the early 1990s, attending the University of Kansas School of Business. He worked in the telecom field for ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship ...

Amid the usual hustle before a big medical conference or industry trade show, editors are often buried under a flood of news ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...

Following the company’s announcement of lackluster results from both its Phase III trials, Novo’s shares dropped nearly 9% pre-market, a significant shift the company hasn’t seen in its shares since ...

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...